Draig Therapeutics
Draig Therapeutics develops neuropsychiatric medicines.
$65MSeries B
Role not disclosedActivity from announced rounds
Canaan Partners is an investment firm whose company directory identifies Draig Therapeutics and Solstice Oncology.
Draig develops neuropsychiatric medicines, while Solstice advances an engineered CTLA-4 antibody for cancer treatment. The recorded history also includes Actualyze AI’s enterprise gateway for model access, request security, budgets and routing. Named regional funds retain separate identities.
Draig Therapeutics develops neuropsychiatric medicines.